Trials Sponsors Conditions Drugs Pricing

Conditions

Adverse Drug Event Bone and Joint Infection Osteomyelitis

Keywords

bone and joint infectionosteomyelitismandibulardenosumab

Outcome Measures

Primary Outcomes (1)

Rate of mandibular osteomyelitis
description of mandibular osteomyelitis
Entire description can be made at the outcome which is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption

Secondary Outcomes (3)

Duration of antibiotics
Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Rate of Treatment Failure
Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
management of mandibular osteomyelitis by medical team
all data are available at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption

Study Arms (1)

mandibular osteomylitis

description of mandibular osteomylitis due to denosumab

Other: mandibular osteomylitis

Interventions

mandibular osteomylitisOther

mandibular osteomylitis

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 90 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

patients having a mandibular osteomylelitis due to DENOSUMAB betwwen 01/01/2013 and 31/12/2018 and managed at the Lyon Bone and joint infection refence Center

You may qualify if:

patients having a mandibular osteomylelitis due to DENOSUMAB

You may not qualify if:

Sponsors & Collaborators

Hospices Civils de Lyon
Otherlead

Study Sites (1)

Hospices Civils de Lyon

Lyon, 69004, France

MeSH Terms

Conditions

OsteomyelitisDrug-Related Side Effects and Adverse Reactions

Condition Hierarchy (Ancestors)

Bone Diseases, InfectiousInfectionsBone DiseasesMusculoskeletal DiseasesChemically-Induced Disorders

Study Officials

TRISTAN FERRY, MD,PhD
Hospices Civils de Lyon
PRINCIPAL INVESTIGATOR

Enrollment

13 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Clinical Research Assistant

Study Record Dates

First Submitted

January 4, 2019

First Posted

January 17, 2019

Study Start

January 1, 2013

Actual (reported)

Denosumab Related Osteonecrossi of the Jaw : : an Emergent and Potentially Complex Bone and Joint Infection

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (1)

mandibular osteomylitis

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (1)

mandibular osteomylitis

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations